SPSanjib Kumar Panda

Sanjib Kumar Panda

*This is an algorithmically generated author record based on publicly available information.

Sanjib Kumar Panda has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    High potency and water dispersible Boswellia extract reduces pain and inflammation in subjects with osteoarthritis of the knee

    by Somashekara Nirvanashetty, Sanjib Kumar Panda

    Background: Boswellia serrata , also known as Indian frankincense, is a medicinal plant that has been used since ancient times in the traditional Indian medicine system, Ayurveda. Historically, Boswellia extract has been used to treat pain associated with osteoarthritis, rheumatoid arthritis, and tendonitis. Methods: In this randomized, double-blind, placebo-controlled study, 60 subjects aged 40 to 75 years, with mild to moderate knee osteoarthritis received either 100 mg once daily of standardized natural Boswellia extract (OLNP-27) or placebo for 8-weeks. The subjects were monitored for outcome measures such as total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, WOMAC subscales (pain, stiffness, and physical function) score and visual analogue score on day 7, 15, 30, and 60 post supplementation. Results: OLNP-27 significantly ( P < .05) reduced the total WOMAC score, pain score, stiffness score, visual analogue score score and improved the physical function than the placebo. OLNP-27 also decreased the inflammatory marker high-sensitivity-CRP significantly compared to placebo group. The statistically significant reduction in pain and stiffness was observed as quickly as 7 days of supplementation with OLNP-27 indicating the quick onset of action. It also was found to be safe and well tolerated during this study. Conclusion: Based on the current study findings, it can be concluded that OLNP-27 is an effective and safe natural option for the management of symptoms associated with osteoarthritis of the knee.

  • A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Comparative Clinical Study to Evaluate the Efficacy and Safety of OLNP-06 versus Placebo in Subjects with Functional Dyspepsia

    by Mpharm Sanjib Kumar Panda, Somashekara Nirvanashetty, Btech Vivek A. Parachur, Mpharm Chakravarthy Krishnamoorthy, Msc Shemanti Dey

    OLNP-06 is ginger extract product standardized to higher amount of total gingerols formulated with proprietary Aqueosome technology. The safety and efficacy of OLNP-06 were evaluated in a randomized, double blind, placebo controlled, parallel group comparative clinical study in subjects with functional dyspepsia (FD). Significant improvements in clinical endpoints were observed during the trial along with excellent safety profile. Fifty subjects aged between 18 and 55 years suffering from FD as per ROME III criteria were enrolled into the study. They were randomized into two treatment groups, one group received OLNP-06, 200 mg twice daily and other group received placebo 200 mg twice daily. The primary efficacy end point was global assessment of overall treatment efficacy (OTE). Secondary efficacy endpoints were elimination rate of three major symptoms (postprandial fullness, upper abdominal bloating and early satiation) and elimination rate for each individual symptom scores. Biochemical and hematological parameters including urine analysis were performed to evaluate the safety of OLNP-06. Out of 50 subjects, 48subjects completed the study. Total 79% of the subjects receiving OLNP-06 and 21% of the subjects receiving placebo (p < .05) were classified as responders according to the assessment of OTE. Elimination rate (score 0) of postprandial fullness, upper abdominal bloating and early satiation was 64% in subjects receiving ONLP-06 compared with 13% in the placebo group (p < .05). OLNP-06 was found to be safe and well tolerated as there was no incidence of treatment-related AE’s. Supplementation of OLNP-06 for 4 weeks significantly reduced dyspeptic symptoms in subjects suffering from FD. Trial Registration: Clinical Trial Registry-India, CTRI/2019/09/021019, Registered on 2 Sep 2019.


  • A Randomized Double-Blind Placebo-Control Study to Assess the Efficacy and Safety of OLNP-05 Versus Placebo for the Treatment of Subjects with Premature Ejaculation

    by Sanjib Kumar Panda, Somashekara Nirvanashetty, Vivek A. Parachur, Nilima Mohanty

    Premature ejaculation (PE) is one of the foremost sex-related health problems among men. The global occurrence ranges from 20% to 30%, according to various studies. PE has a great impact on the men's quality of life, with deleterious effects such as embarrassment, frustration, and feeling of incompetence. Considering the necessity of treatment of PE, this study was planned to compare the efficacy and safety of OLNP-05 versus placebo for treating subjects suffering from PE. In this randomized clinical study, 60 men with PE were enrolled and randomly assigned to receive either OLNP-05 or placebo one capsule twice daily for a period of 8 weeks. Subjects were evaluated during visits on day 1, day 28, and day 56. Mean change from baseline in intravaginal ejaculatory latency time (IELT), improvement in premature ejaculation profile (PEP), and Clinical Global Impression-Improvement scale (CGI-I) were used to assess the efficacy of treatment. P -value <.05 was considered significant. At the end of the treatment, the improvement in IELT score in the OLNP-05 group was remarkably higher than the placebo. Subjects in the OLNP-05 treatment group also reported significantly greater improvement in PEP subscale score. Majority of OLNP-05-treated subjects were found to be in the “much improved” category as per CGI-I assessment. The result confirms the safety and efficacy of OLNP-05, therefore suggesting that OLNP-05 may be a safe and effective intervention for the management of PE. Trial registration: Clinical Trials Registry India (Registration No: CTRI/2017/08/009226, 02/08/2017).